longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AGENUS INC

00847G804

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current Valuation

--P/E
--Stock price
--P/E
Stock price--

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-55.39x148.77%$179.47B
MRNAUSModerna
-24.07x15.53%$75.86B
NTRAUSNatera
-307.52x6.91%$59.15B
CSLLYUSCSL Limited
-22.68x--$58.50B
RVMDUSRevolution Medicines
-25.05x63.01%$44.29B
ROIVUSRoivant Sciences
-96.91x146.49%$25.80B
BNTXUSBioNTech SE
-12.43x17.09%$24.34B
INSMUSInsmed
-27.72x74.61%$24.27B
SMMTUSSummit Therapeutics
-15.61x19.67%$13.37B
BBIOUSBridgebio Pharma
-19.00x28.48%$13.15B
TWSTUSTwist Bioscience
-90.85x20.00%$12.42B
MDGLUSMadrigal Pharma
-35.49x51.06%$11.54B
IBRXUSImmunityBio
-10.98x151.32%$10.90B
CYTKUSCytokinetics
-10.20x6.37%$9.12B
ARWRUSArrowHead Pharma
-28.34x36,308.30%$9.07B
KYMRUSKymera Therapeutics
-29.80x4.94%$8.93B
PCVXUSVaxcyte
-7.90x48.80%$8.40B
PRAXUSPraxis Precision Medicines
-24.33x3.05%$8.25B
SYREUSSpyre Therapeutics
-54.70x46.89%$8.22B
ABVXUSAbivax SA
-17.38x22.49%$8.10B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.